Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|DRUG: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|DRUG: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|DRUG: Ixabepilone + Lapatinib + Capecitabine
Sponsor: R-Pharm
Collaborators: GlaxoSmithKline